Myomo Inc
F:0M61
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Myomo Inc
F:0M61
|
US |
|
P
|
Propel Global Bhd
KLSE:PGB
|
MY |
Myomo Inc
Myomo, Inc. is a medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The company is headquartered in Boston, Massachusetts and currently employs 100 full-time employees. The company went IPO on 2017-06-12. The firm offers functional improvement for those with neuromuscular disorders and upper limb paralysis. The firm develops and markets the MyoPro product line. The MyoPro is a myoelectric-controlled upper limb brace (orthosis). The orthosis is a rigid brace used for the purpose of supporting a patient’s weak or paralyzed arm to enable and help improve functional activities of daily living (ADLs), in the home and community. The MyoPro can enable individuals to self-initiate and control movements of a partially paralyzed or weakened limb using their own muscle signals. The Company’s products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury and other neurological disorders. The company primarily provides devices directly to patients and bills their insurance companies.
Myomo, Inc. is a medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The company is headquartered in Boston, Massachusetts and currently employs 100 full-time employees. The company went IPO on 2017-06-12. The firm offers functional improvement for those with neuromuscular disorders and upper limb paralysis. The firm develops and markets the MyoPro product line. The MyoPro is a myoelectric-controlled upper limb brace (orthosis). The orthosis is a rigid brace used for the purpose of supporting a patient’s weak or paralyzed arm to enable and help improve functional activities of daily living (ADLs), in the home and community. The MyoPro can enable individuals to self-initiate and control movements of a partially paralyzed or weakened limb using their own muscle signals. The Company’s products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury and other neurological disorders. The company primarily provides devices directly to patients and bills their insurance companies.
Revenue: Q4 revenue was $11.4 million and full-year 2025 revenue was $40.9 million, up 26% vs. 2024, with a record 241 orders in the quarter.
Channel shift: Management is pivoting toward recurring patient sources (O&P channel, MyoConnect referrals, international, VA); recurring sources were 42% of Q4 revenue (up from 26% a year earlier).
Payer progress: Signed a multistate arrangement with Elevance Health (covers 45 million lives) and additional in‑network contracts are driving more authorizations, but Medicare Advantage denials remain a headwind.
Margins & cost control: Q4 gross margin was 68.6%; company expects COGS reductions (mobile app, other projects) and to target roughly 70% gross margin exiting 2026 while cutting cash burn ~50% in 2026.
Profitability outlook: 2026 revenue guidance of $43 million–$46 million with OpEx growth limited to roughly half the revenue growth; expect lower operating loss and reduced cash burn.
International & China: Germany grew strongly (Q4 international $2.2M, +46%); China JV operations are on hold after JV partner bankruptcy and management is pursuing recapitalization options.
Product & evidence: Launched MyoPro 2X, developing MyoPro 3, mobile app rolling out soon, and an RCT at University of Utah with first readouts expected later in 2026.
